Company intelligence / Profile preview

iSaffron

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

iSaffron is a preclinical-stage biotechnology company dedicated to the discovery and development of small molecule therapies for neurodegenerative disorders, specifically Parkinson's disease. The company's research centers on modulating protein aggregation, with a primary focus on inhibiting the pathological accumulation of alpha-synuclein. Led by a seasoned management team with extensive experience in drug discovery and successful exits, iSaffron is positioned to advance a pipeline of disease-modifying candidates. The firm is headquartered in San Diego and is supported by leading life science venture capital investors.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on iSaffron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iSaffron.

Explore the full profile